PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12090350-8	2001	The use of COX-2 inhibitors to ameliorate delayed emesis induced by cisplatin-based anticancer chemotherapy has been proposed.	Cisplatin	68-77	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	11-16	
29897076-0	2018	Honey protects against cisplatin-induced hepatic and renal toxicity through inhibition of NF-kappaB-mediated COX-2 expression and the oxidative stress dependent BAX/Bcl-2/caspase-3 apoptotic pathway.	Cisplatin	23-32	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	109-114	
32006559-15	2020	The in vitro study confirmed the inhibitory activity of 6-MeOF for COX-1 and COX-2.6-MeOF may be effective in attenuating cisplatin-induced allodynia, probably through interaction with GABAergic receptors and reducing inflammation.	Cisplatin	122-131	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	77-82	
28413323-10	2017	Moreover, FBG showed protective effects against cisplatin-induced oxidative renal damage in rats through the inhibition of NF-kappaB/p65, COX-2, and caspase-3 activation.	Cisplatin	48-57	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	138-143	
19629487-1	2010	PURPOSE: The purpose of this study was to determine the effects of a nonselective cyclooxygenase (cox) inhibitor and of a selective cox-2 inhibitor on the renal toxicity of cisplatin.	Cisplatin	173-182	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	132-137	
27571604-12	2016	Moreover, enalapril dose dependently inhibited cisplatin-induced inflammation (NF-kappaB/IKK-beta/IL-6/Cox-2/TNF-alpha expressions), apoptosis (increased Bcl-2 and reduced p53, cytochrome c, Bax and caspase-3 expressions, and TUNEL/DAPI positivity) and preserved the structural integrity of the kidney.	Cisplatin	47-56	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	103-108	
24415068-7	2014	Compared to curcumin, CDF had greater potential in suppressing cisplatin-induced pro-inflammatory factors NF-kappaB and COX-2 as well as downstream markers Nrf2 and HO-1 (P < 0.05) in kidney.	Cisplatin	63-72	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	120-125	
21256724-0	2012	Amelioration of cisplatin-induced rat renal lesions by a cyclooxygenase (COX)-2 selective inhibitor.	Cisplatin	16-25	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	57-79	
21256724-2	2012	We investigated effects of a COX-2 selective inhibitor, NS-398, on cisplatin (CDDP)-induced rat renal lesions.	Cisplatin	67-76	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	29-34	
21256724-6	2012	Collectively, although these differences between the CDDP and inhibitor groups were not always marked, the COX-2 inhibitor used in this study could ameliorate the CDDP-induced rat renal lesions.	Cisplatin	163-167	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	107-112	
22319240-6	2011	These findings differed from the decreased COX-2 expression and exclusive nuclear expression of cyclin D1 seen in abnormal epithelial regeneration of injured renal tubules in cisplatin-treated rats in our previous articles.	Cisplatin	175-184	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	43-48	
18248879-9	2008	In addition, CDDP significantly increased the level of COX-2, PGs, and ILs in the late phase (within 24h).	Cisplatin	13-17	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	55-60	
18248879-10	2008	When ERK activity inhibitor (PD98059, 10 microM) or COX-2 activity inhibitor (NS-398, 10 microM) was used, CDDP reduction of TF and induction of PG and IL expression were prevented, suggesting that the detrimental effects on spermatogenesis through the impairment of SC induced by CDDP are mediated by the activation of ERK1/2 and COX-2 pathways in SC.	Cisplatin	107-111	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	52-57	
18248879-10	2008	When ERK activity inhibitor (PD98059, 10 microM) or COX-2 activity inhibitor (NS-398, 10 microM) was used, CDDP reduction of TF and induction of PG and IL expression were prevented, suggesting that the detrimental effects on spermatogenesis through the impairment of SC induced by CDDP are mediated by the activation of ERK1/2 and COX-2 pathways in SC.	Cisplatin	107-111	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	331-336	
18248879-10	2008	When ERK activity inhibitor (PD98059, 10 microM) or COX-2 activity inhibitor (NS-398, 10 microM) was used, CDDP reduction of TF and induction of PG and IL expression were prevented, suggesting that the detrimental effects on spermatogenesis through the impairment of SC induced by CDDP are mediated by the activation of ERK1/2 and COX-2 pathways in SC.	Cisplatin	281-285	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	52-57